Table 1. Summary of Results from Previous Studies Regarding Chemotherapy-Induced Hyperglycemia.
| Study | Region | Study design | Setting (no. of patients, type of cancer, chemotherapy regimen) | Diagnostic tool for DM | Incidence | Risk factor(s) | Glucose-lowering therapy | Outcome | |
|---|---|---|---|---|---|---|---|---|---|
| Previous DM | New DM | ||||||||
| Feng et al. (2013) [11] | China | Retrospective | 362, Colon cancer, 5FU (results incomplete for 44 patients) | FPG | FPG, OGTT | DM: 42 (11.6%) During treatment: 32 After treatment: 10 IFG: 41(11.3%) During treatment: 33 After treatment: 8 |
- | OAD: 22 (52.4%) LSM: 13 (30.9%) Observation: 7 (16.7) |
Persistent: 31 (8.6%) |
| Lipscombe et al. (2013) [16] | Canada | Population-based, retrospective | Early-stage breast cancer vs. no breast cancer | History | 2 Claims or 1 hospitalization | 8.9% in patients who underwent adjuvant therapy, 10.0% in patients who did not undergo adjuvant therapy Age difference |
- | - | - |
| Ji et al. (2013) [17] | China | Retrospective | 119, Breast cancer, chemotherapy | OGTT | OGTT | DM: 21.8% Prediabetes: 43.7% |
- | - | - |
| Lee et al. (2014) [18] | Japan | Retrospective | 80, Lymphoma, CHOP | HbA1c | FPG/random glucose/bA1c | 26 (32.5%) | Age ≥60 yr BMI >30 kg/m2 HbA1c >6.1% |
Insulin: 3 LSM: 1 |
Persistent: 2 (2.5%) |
DM, diabetes mellitus; 5FU, 5-fluorouracil; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; IFG, impaired fasting glucose; OAD, oral antidiabetic drug; LSM, life style modification; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; HbA1c, hemoglobin A1c; BMI, body mass index.